Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Celcuity Inc (CELC)

Celcuity Inc (CELC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 552,858
  • Shares Outstanding, K 37,030
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,780 K
  • EBIT $ -85 M
  • EBITDA $ -85 M
  • 60-Month Beta 0.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.08

Options Overview Details

View History
  • Implied Volatility 142.12% ( +8.51%)
  • Historical Volatility 36.80%
  • IV Percentile 98%
  • IV Rank 94.19%
  • IV High 150.19% on 09/09/24
  • IV Low 11.37% on 06/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 2.82
  • Today's Open Interest 2,207
  • Open Int (30-Day) 2,192

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.65
  • Number of Estimates 5
  • High Estimate -0.55
  • Low Estimate -0.72
  • Prior Year -0.83
  • Growth Rate Est. (year over year) +21.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.06 +9.41%
on 10/10/24
16.49 -6.73%
on 10/23/24
+0.34 (+2.26%)
since 10/04/24
3-Month
13.85 +11.01%
on 09/24/24
18.00 -14.56%
on 08/23/24
-1.90 (-11.00%)
since 08/02/24
52-Week
9.99 +53.95%
on 11/07/23
22.19 -30.68%
on 03/28/24
+4.70 (+44.01%)
since 11/03/23

Most Recent Stories

More News
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

/CNW/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...

ONCY : 1.1650 (-1.27%)
CELC : 15.20 (+1.81%)
OLMA : 12.15 (+4.56%)
BIO : 368.05 (-0.10%)
AZN : 71.40 (-0.03%)
ONC.TO : 1.62 (-2.41%)
Biotech's Developments in Race Against Rising Cancer Rates Revealed

USA News Group – According to a “highly troubling” new study, the rising number of cancer cases in young people is being attributed to “accelerated aging.” Further alarm is being spread by the...

ONCY : 1.1650 (-1.27%)
ONC.TO : 1.62 (-2.41%)
CELC : 15.20 (+1.81%)
OLMA : 12.15 (+4.56%)
BIO : 368.05 (-0.10%)
AZN : 71.40 (-0.03%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

CELC : 15.20 (+1.81%)
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer

MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced...

CELC : 15.20 (+1.81%)
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients...

CELC : 15.20 (+1.81%)
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates

- Entered into $100 Million Private Placement Agreement - Finalized pivotal Phase 3 trial design for gedatolisib - Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast cancer...

CELC : 15.20 (+1.81%)
Celcuity Inc. Announces $100 Million Private Placement

Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage...

CELC : 15.20 (+1.81%)
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients...

CELC : 15.20 (+1.81%)
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients...

CELC : 15.20 (+1.81%)
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates

- Finalized pivotal Phase 3 trial design following formal meetings with FDA - Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer - Presented updated Phase 1b data...

CELC : 15.20 (+1.81%)

Business Summary

Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's...

See More

Key Turning Points

3rd Resistance Point 17.10
2nd Resistance Point 16.52
1st Resistance Point 15.73
Last Price 15.20
1st Support Level 14.36
2nd Support Level 13.78
3rd Support Level 12.99

See More

52-Week High 22.19
Fibonacci 61.8% 17.53
Fibonacci 50% 16.09
Last Price 15.20
Fibonacci 38.2% 14.65
52-Week Low 9.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar